Key Points
- CEO Michael Halstead bought 100,000 Cybin shares at an average price of $13.47, investing approximately $1.35 million and increasing his holdings by about 146% to 168,568 shares.
- Cybin shares opened at $13.66, near their 52-week high of $15.15, but the company reported a quarterly loss of $0.91 per share, missing analysts’ $0.80-loss estimate.
- Analyst sentiment remains broadly positive, with six buy ratings and an average price target of $46.33; recent targets include $62 from TD Cowen and $35 from Barclays.
Cybin Inc. (NASDAQ:HELP - Get Free Report) CEO Michael Halstead bought 100,000 shares of the company's stock in a transaction dated Monday, September 21st. The stock was bought at an average price of $13.47 per share, with a total value of $1,347,000.00. Following the acquisition, the chief executive officer owned 168,568 shares in the company, valued at approximately $2,270,610.96. This trade represents a 145.84% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Cybin Stock Performance
NASDAQ HELP opened at $13.66 on Tuesday. The business's 50 day moving average price is $10.81 and its 200-day moving average price is $7.14. Cybin Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $15.15. The company has a market cap of $1.08 billion, a P/E ratio of -4.52 and a beta of 0.63.
Cybin (NASDAQ:HELP - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). As a group, equities analysts predict that Cybin Inc. will post -2.95 EPS for the current year.
Cybin News Roundup
Here are the key news stories impacting Cybin this week:
- Positive Sentiment: CEO Michael Halstead purchased 100,000 shares at an average price of $13.47, investing approximately $1.35 million and increasing his direct holdings by about 146%. The sizable open-market purchase may be viewed as a signal of management confidence in Cybin’s outlook. SEC Form 4 filing
- Positive Sentiment: Helus Pharma presented four analyses of HLP003, an investigational oral deuterated psilocin analog, at Psych Congress 2026. The presentations further characterize HLP003 and the Phase 3 PARADIGM program, which is evaluating the treatment as an adjunctive therapy for major depressive disorder. Additional clinical data may support the company’s development strategy, although HLP003 remains investigational and faces clinical and regulatory risks. HLP003 Psych Congress presentation
- Positive Sentiment: Cybin is scheduled to participate in the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, where Halstead will join a fireside chat. The event provides an opportunity to discuss the company’s serotonergic pipeline with investors and analysts. TD Cowen summit announcement
- Neutral Sentiment: Brokerage coverage has expanded, with Barclays initiating coverage and brokerages assigning a reported average price target of $48.60. These targets can improve visibility, but they are estimates rather than guarantees of future performance. Barclays coverage initiation
Hedge Funds Weigh In On Cybin
A hedge fund recently bought a new stake in Cybin stock. AXQ Capital LP purchased a new stake in shares of Cybin Inc. (NASDAQ:HELP - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 11,315 shares of the company's stock, valued at approximately $75,000. 17.94% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms recently commented on HELP. Wall Street Zen raised shares of Cybin from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 29th. TD Cowen increased their price objective on shares of Cybin from $8.00 to $62.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Barclays initiated coverage on Cybin in a research note on Friday. They set an "overweight" rating and a $35.00 target price on the stock. Finally, Wells Fargo & Company started coverage on Cybin in a report on Monday, July 27th. They issued an "overweight" rating and a $16.00 price target on the stock. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $46.33.
Check Out Our Latest Stock Analysis on Cybin
About Cybin
(
Get Free Report)
Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments.
Cybin's development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
